KT-301 / Kibow Biotech - LARVOL DELTA

Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (clinicaltrials.gov) - P2 | N=630 | Suspended | Sponsor: Kibow Pharma | Trial completion date: Dec 2023 ➔ Dec 2025 | Recruiting ➔ Suspended | Trial primary completion date: Sep 2023 ➔ Sep 2025

Metastases • Trial completion date • Trial primary completion date • Trial suspension • Chronic Kidney Disease • Nephrology • Renal Disease

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study (clinicaltrials.gov) - P2/3 | N=600 | Suspended | Sponsor: Kibow Pharma | Trial completion date: Mar 2024 ➔ Mar 2026 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Trial suspension • Chronic Kidney Disease • Nephrology • Renal Disease

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study (clinicaltrials.gov) - P2/3 | N=600 | Recruiting | Sponsor: Kibow Pharma | Trial completion date: Mar 2023 ➔ Mar 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease • CRP

Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (clinicaltrials.gov) - P2 | N=630 | Recruiting | Sponsor: Kibow Pharma | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease • CRP

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of US-APR2020 In Subjects With CKD IV Completing The US-APR2020-01 Study (clinicaltrials.gov) - P2/3 | N=600 | Recruiting | Sponsor: Kibow Pharma

New P2/3 trial • Chronic Kidney Disease • Nephrology • Renal Disease • CRP